Le Lézard
Classified in: Health
Subjects: NPT, PER

Foundation for Sarcoidosis Research Announces New Scientific Advisory Board Chair


CHICAGO, Nov. 25, 2020 /PRNewswire/ -- The Foundation for Sarcoidosis Research (FSR), the leading international organization dedicated to advancing research and improving care for individuals living with sarcoidosis, announces the appointment of Elliott Crouser, MD as Chair of the organization's Scientific Advisory Board (SAB).

"Dr. Crouser is exceptionally well-respected and a leader in the sarcoidosis research and treatment field," Chair of FSR Board of Directors, Louise Perkins, said. "We are thrilled that he will lead our Scientific Advisory Board, an esteemed group of dedicated researchers, scientists and physicians at the forefront of fighting against sarcoidosis."

Dr. Crouser has over 31 years of medical experience and has been a member of FSR's SAB since 2016. He is a professor of medicine at Ohio State University where he specializes in Pulmonary and Critical Care Medicine with a focus on translational research on systemic inflammatory diseases involving the lungs.  In 25 years of supported research, Dr. Crouser's laboratory has contributed to the publication of more than 100 peer-reviewed manuscripts, including the first efforts to study sarcoidosis disease mechanisms by deeply scrutinizing genetic data (2009) and the first clinical practice guidelines for sarcoidosis which were endorsed by the American Thoracic Society in 2020.

In addition to his research, Dr. Crouser served as the President of the American Association of Sarcoidosis and Other Granulomatous Disorders (AASOG) from 2017-2019 and has advocated for the sarcoidosis community through engagement with the National Institutes of Health.

"As Chair of FSR's SAB, I look forward to working with my colleagues who share my commitment to advancing research and improving health outcomes for sarcoidosis patients. We strive to elevate the priority for sarcoidosis research to promote sustainable funding and foster mentorship opportunities for engaging talented young investigators to address the many unmet needs of sarcoidosis patients, including providing more personalized, disease-specific treatments." 

The Foundation for Sarcoidosis Research maintains an international Scientific Advisory Board composed of 20 world-renowned key opinion leaders within the fields of sarcoidosis, medical research, therapy development, and medical practice. "We are honored to have Dr. Crouser at the helm of FSR's SAB. The SAB is integral in providing critical insight, scientific direction, and expertise to the Foundation as we work towards better patient outcomes, more timely diagnosis, improved treatment options and providing opportunities for patient support and care," said FSR's CEO, Mary McGowan. For a complete listing of FSR's SAB members please visit stopsarcoidosis.org/SAB.

About Sarcoidosis

Sarcoidosis is a rare inflammatory disease that causes cells to form clumps called granulomas. When too many granulomas form on an organ, they can interfere with the organ's function. Sarcoidosis can affect any organ in the body; however, 90 percent of cases impact the lungs.

About the Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research is the leading international organization dedicated to finding a cure for sarcoidosis and to improving care for sarcoidosis patients. Since its establishment in 2000, FSR has fostered over $5 million in sarcoidosis-specific research efforts. For more information about FSR visit: stopsarcoidosis.org

CONTACT: Maggie Hudson, maggie@stopsarcoidosis.org

 

SOURCE Foundation for Sarcoidosis Research


These press releases may also interest you

at 00:00
Surrey physician, Dr. Sachit Shah, of Beautiful Canadian Laser and Skincare Clinic, has been approved as the first doctor in B.C. to offer non-surgical facelifts using a newer, Health Canada approved thread material. "This is a very fast and...

22 jan 2021
The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine's efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of...

22 jan 2021
The Alisal Guest Ranch and Resort has partnered with biosafety company R-Zero, incorporating the company's hospital-grade UV-C technology into its disinfection protocols to ensure a safe reopening for guests and staff amid the COVID-19 pandemic. The...

22 jan 2021
The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals' LupkynisTM (voclosporin) as the first oral treatment developed specifically for adults with active...

22 jan 2021
For the second time in less than two months, the U.S. Food and Drug Administration (FDA) has approved a new medication to treat adults with lupus nephritis (lupus-related kidney disease) in combination with a background immunosuppressive therapy...

22 jan 2021
Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult...



News published on 25 november 2020 at 10:10 and distributed by: